TrialBritish journal of haematology2019

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Heinz Gisslinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.